NPM1 and acute myeloid leukemia: NPM1-mutated AML patients attained CR and CRi at 80% and 100% in the venetoclax combined with 5 + 2 (cytarabine + idarubicin) study and venetoclax combined with FLAG + IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) study, respectively (ACTRN12616000445471, NCT03214562) (27, 28).